Vertessen, Karen http://orcid.org/0000-0001-8601-6406
Luman, Marjolein http://orcid.org/0000-0002-1539-2831
Bet, Pierre http://orcid.org/0000-0001-6735-7379
Bergwerff, Catharina E. http://orcid.org/0000-0002-5837-3497
Bottelier, Marco http://orcid.org/0000-0003-1428-4123
Stoffelsen, Reino
Swanson, James M.
Wisse, Annemiek
Twisk, Jos
Oosterlaan, Jaap http://orcid.org/0000-0002-0218-5630
Funding for this research was provided by:
Innovatiefonds Zorgverzekeraars (p3119)
Article History
Accepted: 3 November 2023
First Online: 27 January 2024
Declarations
:
: This study is part of the project ‘Reduce and optimize methylphenidate use in children and adolescents with ADHD’ (Grant p3119), funded by Innovation Fund of Health Insurances (Innovatiefonds Zorgverzekeraars). The funder/sponsor did not participate in the work.
: Karen Vertessen has been involved in a clinical trial sponsored by Takeda. The other authors have no conflicts of interest relevant to this article to disclose.
: The local ethics committee approved the study (METC Amsterdam UMC, 2016.594) and the study was registered prospectively in the Dutch trial register (NL8121).
: Parents and children older than 11 years provided signed informed consent.
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: The code used to analyze the data in the current study are available from the corresponding author on reasonable request.
: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by MB, RS, KV and AW. Professor JT was the statistical expert for this study. The first draft of the manuscript was written by KV and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript and agree to be accountable for the work.